<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Praveen Govender, MB Bch</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marco C Post, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3653540808"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sarcoidosis is a multisystemic disease of unknown etiology that is characterized pathologically by nonnecrotizing granulomatous inflammation. Sarcoidosis-associated pulmonary hypertension (SAPH) is increasingly recognized as a complication of sarcoidosis. The diagnosis of SAPH is often delayed and is associated with a poor prognosis. Thus, early recognition and management is important so that patients can be treated promptly.</p><p>This topic will review the epidemiology, pathogenesis, and diagnostic evaluation of SAPH. The treatment of SAPH and diagnosis and management of other complications of sarcoidosis are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4359.html" rel="external">"Treatment of pulmonary sarcoidosis: Initial approach"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5586.html" rel="external">"Sarcoid myopathy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/113435.html" rel="external">"Sarcoidosis of bone"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13773.html" rel="external">"Cutaneous sarcoidosis: Management"</a>.)</p><p></p><p>Several societies have provided guidance on the evaluation and management of SAPH including the American Thoracic Society [<a href="#rid1">1</a>] and the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) [<a href="#rid2">2</a>]. Our recommendations are mostly in keeping with this guidance.</p><p class="headingAnchor" id="H571630589"><span class="h1">DEFINITION AND CLASSIFICATION</span><span class="headingEndMark"> — </span>Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure (mPAP) &gt;20 mmHg at rest, measured by right heart catheterization. Although poorly defined, PH is considered severe if mPAP is ≥35 mmHg or if mPAP is &gt;20 mmHg with a right atrial pressure &gt;14 mmHg, pulmonary vascular resistance (PVR) &gt;5 Wood units (WU), and/or cardiac index &lt;2 L/min/m<sup>2</sup> [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Diagnosis'</a>.)</p><p>Patients with PH are classified into five groups based upon etiology and mechanism  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. SAPH is typically classified as group 5 (PH due to unclear or multifactorial mechanisms) since the cause is multifactorial. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 5: PH due to multifactorial mechanisms'</a>.)</p><p>Patients with sarcoidosis may have contributions from one or more classes including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Group 1 (pulmonary arterial hypertension; rare)</p><p class="bulletIndent1"><span class="glyph">●</span>Group 2 (PH due to left-sided heart disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Group 3 (PH due to chronic lung diseases or hypoxemia)</p><p class="bulletIndent1"><span class="glyph">●</span>Group 4 (PH due to chronic thromboembolic disease or pulmonary artery obstruction)</p><p class="bulletIndent1"><span class="glyph">●</span>Group 5 (PH due to several mechanisms including contributions for comorbidities, such as sleep apnea or portal hypertension)</p><p></p><p>The contribution from each class may vary such that a patient may have one class as the dominant form of PH while another patient may have mixed components from more than one class.</p><p>PH may also be subcategorized hemodynamically as the following  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Precapillary PH – mPAP &gt;20 mmHg with pulmonary artery wedge pressure (PAWP) ≤15 mmHg and PVR ≥3 WU.</p><p class="bulletIndent1"><span class="glyph">●</span>Postcapillary PH – mPAP &gt;20 mmHg with PAWP &gt;15 mmHg and PVR &lt;3 WU.</p><p class="bulletIndent1"><span class="glyph">●</span>Combined pre- and postcapillary PH (Cpc-PH) – mPAP &gt;20 mmHg with PAWP &gt;15 mmHg and PVR ≥3 WU.</p><p></p><p class="headingAnchor" id="H2422127653"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Among patients with sarcoidosis, the average incidence of SAPH is approximately 5 percent but ranges from 2 to 21 percent [<a href="#rid5">5-17</a>]. The distribution of SAPH is worldwide, and there appears to be no racial, ethnic, age, or sex predilection [<a href="#rid18">18,19</a>].</p><p>Several factors influence SAPH rates including different definitions (eg, mean pulmonary artery pressure [mPAP] ≥25 mmHg, mPAP &gt;20 mmHg), the method used to assess PH (eg, transthoracic echocardiogram [TTE] versus right heart catheterization [RHC]), and different study populations (eg, general population versus pretransplant patients).</p><p>Most studies have used TTE to identify PH, which have likely overestimated the incidence of SAPH. By contrast, most studies that used RHC employed a threshold mPAP ≥25 mmHg for the diagnosis of PH rather than the revised threshold of &gt;20 mmHg, which has likely underestimated the incidence of SAPH [<a href="#rid5">5,9,12,14,15,20,21</a>]. The best data comes from a cumulative analysis of two separate European cohorts totaling 510 patients with sarcoidosis [<a href="#rid14">14,15</a>], which estimated that the prevalence of TTE-defined PH was 10 percent and RHC-defined PH (mPAP ≥25 mmHg) was 2.9 percent [<a href="#rid12">12</a>].</p><p>Rates are higher among those with severe pulmonary disease. For example, among sarcoidosis patients with signs and symptoms of PH, the prevalence of SAPH approaches 50 percent [<a href="#rid6">6,22</a>], and among those awaiting lung transplantation, the prevalence increases to 74 percent [<a href="#rid13">13,23,24</a>].</p><p>It is unclear if there is a predominant PH phenotype in patients with sarcoidosis. Although data vary from study to study, collectively, they suggest that most patients phenotypically behave as class 3 PH [<a href="#rid5">5,12,25</a>]. In the largest series to date of patients with SAPH, 70 percent had evidence of class 3 PH, 17.5 percent had evidence of class 4 PH (mostly due to compression of pulmonary vasculature), 7.5 percent had evidence of class 2 PH, and &lt;1 percent had evidence of group 1 pulmonary arterial hypertension [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1609243862"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>In pulmonary sarcoidosis, a variety of mechanisms can lead to SAPH. Because several mechanisms contribute to SAPH, it is most often classified as group 5 PH, but patients with SAPH may have dominant features of any one of the classes of PH or have combined features of one or more class  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>). (See <a class="local">'Definition and classification'</a> above and <a class="local">'Postdiagnostic testing and phenotyping'</a> below.)</p><p class="headingAnchor" id="H2495282747"><span class="h2">Cardiac dysfunction</span><span class="headingEndMark"> — </span>Sarcoidosis-related left ventricular (LV) systolic or diastolic dysfunction has been implicated in the pathogenesis of SAPH (ie, group 2 PH) [<a href="#rid26">26-28</a>], which can be exacerbated by coexistent comorbidities (eg, obesity [<a href="#rid29">29</a>] and systemic arterial hypertension [<a href="#rid30">30</a>]).</p><p>The exact contribution of cardiac dysfunction to SAPH is unclear. One study of 130 patients with suspected SAPH, estimated that among those who had PH, almost one-third had PH with LV dysfunction [<a href="#rid31">31</a>]. Another study reported postcapillary PH in only 7.5 percent of patients with right heart catheterization-confirmed PH [<a href="#rid25">25</a>].</p><p>Manifestations and diagnostic evaluation of suspected cardiac sarcoidosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p class="headingAnchor" id="H439796867"><span class="h2">Pulmonary parenchymal disease</span><span class="headingEndMark"> — </span>Progressive fibrotic lung disease due to sarcoidosis has been implicated in the pathogenesis of SAPH (ie, group 3 PH phenotype). Hypoxic vasoconstriction and obliteration of the pulmonary vascular bed are suggested mechanisms in this population. In support of this mechanism, PH is common in those with severe lung disease requiring lung transplant (eg, &gt;65 percent) [<a href="#rid18">18,19,32</a>]. However, PH does not always correlate well with the degree of pulmonary fibrosis [<a href="#rid6">6,7,33,34</a>], suggesting other mechanisms are also involved.</p><p class="headingAnchor" id="H1010185869"><span class="h2">Pulmonary vascular disease</span><span class="headingEndMark"> — </span>The spectrum of vascular mechanisms leading to SAPH is broad and includes sarcoidosis-related vasculopathy, direct vascular involvement by sarcoid granulomas, compression of the pulmonary vasculature by lymphadenopathy or mediastinal fibrosis, and venous thromboembolic (VTE) disease.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculopathy</strong> – While some patients with SAPH have a precapillary pulmonary arterial hypertension (PAH) phenotype, whether the same proliferative vasculopathy that is present in patients with PAH occurs in SAPH is unknown. The pathogenesis of PAH is discussed separately. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct vascular involvement</strong> – Granulomatous angiitis has been reported by several groups. As an example, several pathologic studies that have examined lung tissue obtained at autopsy, transbronchial biopsy, or from explanted lung have shown that the pulmonary vasculature is frequently involved by granulomatous inflammation, irrespective of sarcoidosis stage on the chest radiograph [<a href="#rid33">33,35-38</a>].</p><p></p><p class="bulletIndent1">Involvement is most often perivenular (61 to 65 percent) but may also be arterial (11 percent) or venoarterial (24 to 31 percent)  (<a class="graphic graphic_diagnosticimage graphicRef142509" href="/d/graphic/142509.html" rel="external">image 1</a>). Granulomatous angiitis can lead to perivascular fibrosis and an occlusive vasculopathy. When this occurs in the small veins, it may lead to a rare mechanism of SAPH similar clinically to pulmonary veno-occlusive disease (PVOD) [<a href="#rid39">39-41</a>]. The pathogenesis of PVOD is discussed separately. (See  <a class="medical medical_review" href="/d/html/8269.html" rel="external">"Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults", section on 'Pathogenesis and risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrinsic pulmonary artery compression</strong> – SAPH has been reported to occur in the setting of extrinsic compression of the pulmonary arteries [<a href="#rid42">42,43</a>] and pulmonary veins by enlarged and/or calcified mediastinal lymph nodes or by mediastinal fibrosis [<a href="#rid44">44,45</a>]. Left atrial compression by lymphadenopathy is another potential mechanism that may be evident on computed tomographic (CT) imaging [<a href="#rid46">46,47</a>]. It should be noted that PH due to extrinsic compression is not considered true group 4 PH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolic (VTE) disease</strong> – Several population-based studies identified a two- to threefold increased risk of acute VTE in patients with sarcoidosis, which may contribute to the development or worsening of PH in this population [<a href="#rid48">48-50</a>]. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p></p><p class="bulletIndent1">In addition, chronic thromboembolic PH has also been reported in patients with sarcoidosis [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"</a>.)</p><p></p><p class="headingAnchor" id="H3389974535"><span class="h2">Contributing comorbidities</span><span class="headingEndMark"> — </span>Sarcoidosis is associated with comorbidities that may contribute to the pathogenesis of SAPH, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructive sleep apnea (OSA)</strong> – There is a high prevalence of OSA reported in patients with sarcoidosis (&gt;50 percent) [<a href="#rid52">52-56</a>]. Patients with OSA may have nocturnal intermittent hypoxemia, which can induce pulmonary vasoconstriction and worsen PH. Glucocorticoids, as a treatment for sarcoidosis, may also increase the risk of OSA [<a href="#rid56">56</a>]; whether this potential mechanism is counterbalanced by improvement in underlying lung disease is unclear. (See  <a class="medical medical_review" href="/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults", section on 'Sleep disordered breathing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Portopulmonary hypertension (POPH)</strong> – Although portal hypertension is rare in this population, POPH has been reported in the setting of sarcoid-related hepatic involvement [<a href="#rid57">57,58</a>]. (See  <a class="medical medical_review" href="/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis", section on 'Hepatic'</a>.)</p><p></p><p class="headingAnchor" id="H286019167"><span class="h1">IDENTIFICATION OF AT-RISK PATIENTS</span></p><p class="headingAnchor" id="H368193427"><span class="h2">Algorithmic overview</span><span class="headingEndMark"> — </span>In patents with an established diagnosis of sarcoidosis, we have a low threshold to suspect PH. However, recognizing PH is challenging as the signs and symptoms of PH overlap with those of pulmonary parenchymal and cardiac sarcoidosis. This frequently leads to a delay in the diagnosis, sometimes as long as 15 years [<a href="#rid18">18</a>]. Our overall approach is as follows  (<a class="graphic graphic_algorithm graphicRef143084" href="/d/graphic/143084.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with sarcoidosis, we pay close attention to select signs and symptoms of PH, pulmonary function tests (PFTs), and imaging features, much of which is often performed during diagnostic evaluation and follow-up. (See <a class="local">'Symptoms and signs'</a> below and <a class="local">'Pulmonary function testing'</a> below and <a class="local">'Imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once clinically suspected, we generally repeat chest CT and PFTs if they have not recently been performed (eg, previous 12 months). We additionally perform indices of oxygenation (eg, peripheral oxygen saturation (SpO<sub>2</sub>), six-minute walk test [6MWT]) and assess for right ventricular (RV) strain by obtaining brain natriuretic peptide (BNP) levels and electrocardiography (ECG). (See <a class="local">'Oxygenation and six-minute walk test'</a> below and <a class="local">'Laboratory testing'</a> below and <a class="local">'Electrocardiography'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using this information, we select patients for diagnostic testing, typically transthoracic echocardiography (TTE). (See <a class="local">'Diagnostic evaluation'</a> below and <a class="local">'Transthoracic echocardiography (TTE)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TTE findings together with clinical findings determine who undergoes right heart catheterization. (See <a class="local">'Selecting patients for right heart catheterization'</a> below.)</p><p></p><p class="headingAnchor" id="H1165130203"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>SAPH is most commonly seen as a late complication in long-established pulmonary sarcoidosis [<a href="#rid32">32,59,60</a>], although detection early in the course has been described [<a href="#rid61">61</a>].</p><p>The most common initial symptom of SAPH is progressive exertional dyspnea [<a href="#rid6">6</a>]. We maintain a high suspicion for SAPH in patients with sarcoidosis who have any one or more of the following [<a href="#rid18">18,22,62,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea that is either unexplained or disproportionately severe in comparison to imaging, spirometry, and lung volume assessment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea that is persistent or severe despite anti-inflammatory therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea that is new in onset or associated with worsening functional class  (<a class="graphic graphic_table graphicRef62080" href="/d/graphic/62080.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exertional chest pain, syncope, or other manifestations of right-sided heart failure (eg, fatigue, lower extremity edema, anorexia, and increased abdominal girth due to ascites, loud pulmonic component of second heart sound).</p><p></p><p>These symptoms, while suspicious for PH, are nonspecific and can overlap with cardiac or pulmonary parenchymal sarcoidosis [<a href="#rid64">64</a>]. Symptoms such as weight gain with fluid retention can also occur in patients receiving glucocorticoid therapy for sarcoidosis.</p><p>Symptoms which occur in sarcoidosis that are <strong>not</strong> suggestive of PH include cough and wheezing.</p><p class="headingAnchor" id="H3519332895"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>If SAPH is suspected, we obtain a full set of PFTs, if not recently performed. PFTs include spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO).</p><p>The suspicion for PH should be raised when any of the following is present [<a href="#rid6">6,8,10,18,65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The DLCO is disproportionately lower than that expected for the degree of lung function as measured by the forced vital capacity (FVC). Although an FVC/DLCO ratio &gt;1.6 has been proposed as a predictive factor for systemic sclerosis-related PH, the same ratio has not been adequately studied as a predictor for SAPH. (See  <a class="medical medical_review" href="/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening", section on 'Abnormal pulmonary function (low diffusion)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The DLCO is &lt;50 percent predicted in the absence of pulmonary fibrosis on imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The DLCO is &lt;30 percent with evidence of pulmonary fibrosis (ie, stage 4 sarcoidosis on chest radiography).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A decrease in DLCO by 15 percent without change in lung volumes.</p><p></p><p>While useful, PFTs have poor predictive capacity and there is no absolute value of FVC or DLCO that can accurately predict SAPH. In addition, near-normal lung function does not exclude the diagnosis. In a study of 127 patients with sarcoidosis who had "near-normal" lung function (FVC &gt;70 percent, forced expiratory volume in one second &gt;70 percent, and DLCO &gt;60 percent), the prevalence of SAPH detected by TTE (RV systolic pressure &gt;40 mmHg) was as high as 28.3 percent [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H253096804"><span class="h2">Imaging</span></p><p class="headingAnchor" id="H2012643232"><span class="h3">Chest radiograph</span><span class="headingEndMark"> — </span>The presence of stage 4 sarcoidosis (eg, extensive bronchovascular disease, pulmonary fibrosis) is a risk factor for development of SAPH and usually warrants evaluation with TTE  (<a class="graphic graphic_diagnosticimage graphicRef142500" href="/d/graphic/142500.html" rel="external">image 2</a>). However, patients without evidence of pulmonary sarcoidosis may still have PH  (<a class="graphic graphic_diagnosticimage graphicRef142510" href="/d/graphic/142510.html" rel="external">image 3</a>). (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Chest radiograph'</a>.)</p><p class="headingAnchor" id="H1203376542"><span class="h3">Chest computed tomography</span><span class="headingEndMark"> — </span>When SAPH is suspected, we perform chest CT, if not recently performed [<a href="#rid59">59,60,67,68</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Chest CT can confirm extensive parenchymal sarcoidosis, which is a risk factor for SAPH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest CT can identify other contributors to SAPH, such as mediastinal adenopathy (calcified or noncalcified) and mediastinal fibrosis that may compress and restrict blood flow in pulmonary vessels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest CT allows assessment of other features suggestive of SAPH including the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enlarged pulmonary artery diameter (corrected to the patient's body surface area)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enlarged main pulmonary artery diameter to ascending aorta diameter ratio (PA:AA diameter ≥1)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enlarged RV</p><p></p><p class="headingAnchor" id="H2922664770"><span class="h3">Other imaging</span><span class="headingEndMark"> — </span>RV or pulmonary artery enlargement incidentally noted on other imaging (eg, cardiac magnetic resonance imaging, abdominal CT) raises suspicion for SAPH and should prompt evaluation with TTE.</p><p class="headingAnchor" id="H2317285786"><span class="h2">Oxygenation and six-minute walk test</span><span class="headingEndMark"> — </span>When SAPH is suspected, we perform a formal 6MWT. Both reduced six-minute walk distance (eg, &lt;350 m) and ambulatory oxygen desaturation (eg, &lt;90 percent) are associated with a diagnosis of SAPH [<a href="#rid8">8,18,19,60,69</a>]. There is a strong inverse correlation between 6MWT and presence of SAPH [<a href="#rid60">60</a>], with the relationship being stronger with walk distances &lt;350 m. One series reported that patients who desaturate below 90 percent during the 6MWT were approximately 12 times more likely to have SAPH [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults", section on 'Six-minute walk test'</a>.)</p><p>Hypoxemia at rest, measured by SpO<sub>2</sub> or by arterial blood gas, is another key predictor of SAPH [<a href="#rid6">6,8,13,18,19,60,70</a>]. For example, in 363 patients with sarcoidosis who were listed for lung transplantation, poor oxygenation was the only independent risk factor for the presence of SAPH [<a href="#rid13">13</a>].</p><p>However, in sarcoidosis, poor oxygenation parameters and reduced six-minute walk distances are not diagnostic of PH and can be affected by a variety of factors independent of PH, including musculoskeletal disease, cardiac dysfunction, parenchymal lung disease, depression, and fatigue [<a href="#rid7">7</a>].</p><p>We do not perform advanced cardiopulmonary exercise testing unless the etiology of dyspnea is unclear after evaluation. (See  <a class="medical medical_review" href="/d/html/120609.html" rel="external">"Cardiopulmonary exercise testing in the evaluation of unexplained dyspnea"</a>.)</p><p class="headingAnchor" id="H3480177593"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>There are no serologic tests that definitively identify SAPH. We typically measure BNP or N-terminal pro-BNP (NT-proBNP). While elevated BNP or NT-proBNP may reflect RV strain from SAPH, they are nonspecific and may alternatively indicate the presence of cardiac sarcoidosis [<a href="#rid7">7,60,71</a>].</p><p class="headingAnchor" id="H2676372849"><span class="h2">Electrocardiography</span><span class="headingEndMark"> — </span>Patients with sarcoidosis typically undergo annual ECG monitoring for detection of potential cardiac involvement. While ECG abnormalities such as p-pulmonale, right axis deviation, RV hypertrophy or strain, and right bundle branch block can be observed in patients with cardiac sarcoidosis, they are more likely indicators of significant SAPH. Patients with these ECG features should undergo evaluation for PH with TTE. Conversely, it is important to note a normal ECG does not exclude the diagnosis of SAPH. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Electrocardiography'</a>.)</p><p class="headingAnchor" id="H2095206260"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>For patients with symptoms in whom PH is suspected, the differential diagnosis includes a wide spectrum of cardiopulmonary and other disorders, most of which are distinguished by routine investigations performed for PH. Further details regarding this differential are provided separately. (See  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial differential diagnosis'</a>.)</p><p>Cardiac and pulmonary parenchymal involvement with sarcoidosis are the major conditions that require differentiating. Chest CT, transthoracic echocardiography, and right heart catheterization are often key steps that provide clues to differentiate these conditions. (See <a class="local">'Diagnostic evaluation'</a> below and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H172774647"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1430313121"><span class="h2">Forming an individualized diagnostic strategy</span><span class="headingEndMark"> — </span>For patients at risk for SAPH, we use a multidisciplinary team (MDT) of sarcoidosis and PH experts to facilitate an appropriate diagnostic strategy for each patient  (<a class="graphic graphic_algorithm graphicRef143084" href="/d/graphic/143084.html" rel="external">algorithm 1</a>). The MDT is particularly crucial for deciding who should get transthoracic echocardiography (TTE) and subsequent right heart catheterization (RHC). This approach is outlined in more detail below, but can be briefly summarized:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with both clinical symptoms and objective findings on physical examination, chest imaging, pulmonary function tests (PFTs), electrocardiography, or six-minute walk test (6MWT) suggesting risk for SAPH (see <a class="local">'Identification of at-risk patients'</a> above), we typically pursue further evaluation with TTE. We do <strong>not</strong> routinely perform TTE in asymptomatic patients or patients without risk factors PH  (<a class="graphic graphic_table graphicRef142511" href="/d/graphic/142511.html" rel="external">table 4</a>) [<a href="#rid1">1,2</a>]. (See <a class="local">'Transthoracic echocardiography (TTE)'</a> below and <a class="local">'Identification of at-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We then use TTE assessment in conjunction with clinical findings and the expected need for and type of therapeutic intervention to select patients for RHC. (See <a class="local">'Selecting patients for right heart catheterization'</a> below.)</p><p></p><p class="headingAnchor" id="H4148911924"><span class="h2">Transthoracic echocardiography (TTE)</span><span class="headingEndMark"> — </span>There is no ideal approach or agreed upon criteria to select patients for TTE. For patients in whom clinical features and/or objective testing raise the suspicion for SAPH, we perform TTE rather than routinely performing TTE in every patient with sarcoidosis [<a href="#rid1">1,2</a>].</p><p>In our practice, we perform TTE in symptomatic patients who have one or more objective findings listed on the table  (<a class="graphic graphic_table graphicRef142511" href="/d/graphic/142511.html" rel="external">table 4</a> and <a class="graphic graphic_algorithm graphicRef143084" href="/d/graphic/143084.html" rel="external">algorithm 1</a>) (see <a class="local">'Identification of at-risk patients'</a> above).</p><p>While this selective approach to TTE assessment is like that used in patients with suspected PH from nonsarcoidosis etiologies, only limited data support it in patients with sarcoidosis. It has been estimated that if TTE is performed in patients with clinically suspected SAPH, 29 percent will be abnormal, among which PH would be confirmed by RHC in approximately three-quarters and excluded in the remainder [<a href="#rid1">1</a>]. One prospective study in 479 "unscreened" patients with sarcoidosis found an intermediate and high PH probability on TTE  (<a class="graphic graphic_table graphicRef120360" href="/d/graphic/120360.html" rel="external">table 5</a>) in 6 and 2.7 percent of patients, respectively, and confirmed PH in 3.5 percent [<a href="#rid72">72</a>].</p><p>The value of TTE may be more limited in a significant subset (up to 50 percent) of patients with sarcoidosis due to inability to detect or adequately measure tricuspid regurgitant velocity (TRV) [<a href="#rid22">22,72</a>].</p><p class="bulletIndent1">We discuss the results of TTE and our clinical findings with the MDT to determine subsequent testing, typically RHC. Indications for RHC are discussed below. (See <a class="local">'Selecting patients for right heart catheterization'</a> below.)</p><p></p><p class="headingAnchor" id="H793187888"><span class="h2">Selecting patients for right heart catheterization</span><span class="headingEndMark"> — </span>RHC is the gold standard for the diagnosis of PH, but it is costly, resource-limited, and an invasive procedure. We use RHC in diagnostic evaluation of SAPH to establish a definitive diagnosis of PH (when needed), assess for evidence of left-heart disease, and longitudinally evaluate the potential hemodynamic benefits of a therapeutic intervention. (See  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p>Patient selection for RHC depends upon TTE findings, clinical suspicion for SAPH, and the impact of testing on the decision to implement potential future therapies. When selecting patients with suspected SAPH for RHC, we use a similar strategy to those without sarcoidosis in whom PH is suspected [<a href="#rid4">4</a>]. However, our threshold to perform RHC is typically lower in this population. In our experience, RHC is often needed in suspected SAPH since it can distinguish precapillary from postcapillary disease (ie, group 1, 3, and 4 from group 2 PH phenotype)  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), determine whether PH is multifactorial in nature, and therefore accurately inform therapeutic decisions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TTE</strong> <strong>findings</strong> – TTE plays a key role in deciding who is selected for RHC. We use a strategy that was outlined by the European Society of Cardiology/European Respiratory Society (ECS/ERS) for assessing the likelihood of the presence of PH on echocardiography [<a href="#rid4">4</a>]. This standardized approach stratifies PH probability into low, intermediate, or high based on the maximal TRV and measurements of secondary echocardiographic signs for PH in the right ventricle, right atria/inferior vena cava, and pulmonary artery diameter  (<a class="graphic graphic_table graphicRef120360" href="/d/graphic/120360.html" rel="external">table 5</a>). General principles of patient selection for RHC on TTE findings are the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In those with a low probability of having PH on TTE, we do not generally perform RHC (although there may be exceptions). For most patients with a high probability of PH on TTE, we perform RHC unless RHC would not change management; RHC is performed to make a definitive diagnosis, clarify the PH subtype (when needed), and/or obtain a baseline assessment prior to a therapeutic trial. We assess patients with intermediate probability or inconclusive TTE on a case-by-case basis. Further details regarding this assessment are provided elsewhere:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Low probability of pulmonary hypertension on echocardiography'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Intermediate or high probability of pulmonary hypertension on echocardiography (assess left heart)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with evidence of left ventricular systolic dysfunction on TTE, investigations targeted at possible cardiac involvement with sarcoidosis is reasonable before making a decision about performing a RHC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of PH</strong> – Specific clinical management questions may also influence the decision to proceed with RHC independent of TTE-based assessment of PH likelihood (eg, evaluation for lung transplantation, severe otherwise unexplained dyspnea, uncertain cardiac sarcoidosis contribution to disease). RHC may also be appropriate in patients with a strong clinical suspicion for SAPH based on symptoms, hypoxemia, or PFTs despite a low probability on TTE. This approach is similar to that used for patients with suspected PH without sarcoidosis. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'</a> and <a class="local">'Identification of at-risk patients'</a> above.)</p><p></p><p class="headingAnchor" id="H1867024870"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A definitive diagnosis of SAPH is made based on right heart catheterization (RHC) demonstrating an elevated mean pulmonary artery pressure &gt;20 mmHg while supine and at rest.</p><p>However, in some patients, we consider a diagnosis of "likely SAPH" in the absence of RHC data using clinical and noninvasive testing. For example, SAPH is likely in patients with minimal symptoms who have an intermediate or high probability of PH on echocardiography that is not explained by significant left heart disease and/or by chronic lung disease due to sarcoidosis. However, treatment decisions that involve PH-specific therapy should never be made in patients without a definitive diagnosis by RHC. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Definitions'</a> and  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p class="headingAnchor" id="H3170902241"><span class="h1">POSTDIAGNOSTIC TESTING AND PHENOTYPING</span><span class="headingEndMark"> — </span>As with other patients diagnosed with PH, the postdiagnostic evaluation focuses on identifying the predominant pathophysiology/phenotype and other contributing comorbidities. This assessment is best performed as a collaborative effort between experts in sarcoidosis and PH. Once the relative contribution of various etiologies and the dominant phenotype have been determined, a therapeutic plan can be put into place. (See  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults", section on 'PH phenotype-targeted therapy'</a>.)</p><p>Among the five primary PH classifications  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>), which are based upon etiology and mechanism, SAPH may either have a single dominant phenotype or have combined contributions from more than one etiology:</p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoid-related cardiac dysfunction (leading to dominant group 2 PH phenotype)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoid-related pulmonary parenchymal disease (leading to dominant group 3 PH phenotype)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoid-related pulmonary vascular involvement (thromboembolism, leading to group 4 dominant PH phenotype or direct obstruction of the pulmonary artery)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined mechanisms (leading to group 5 PH)</p><p></p><p>SAPH is mostly classified as group 5 PH since the pathogenesis is often multifactorial (see <a class="local">'Pathogenesis'</a> above). Among the SAPH phenotypes, group 3 PH is the most common while group 1 pulmonary arterial hypertension phenotype is rare in sarcoidosis. The distribution of subclass phenotypes in SAPH is described above. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Definition and classification'</a> above.)</p><p>To fully evaluate contributions from individual etiologies and assess contributing roles of any other comorbidities, adjunct testing may be needed. For example, on a case-by-case basis, we evaluate the need for the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CT pulmonary angiography (CTPA)</strong> – In patients with right heart catheterization-confirmed SAPH, we typically obtain CTPA, if not already performed. The enhancement of the pulmonary vasculature with contrast in CTPA, which is not obtained with chest CT, can identify arterial and veno-atrial compression, segmental arterial and venous occlusion, or chronic pulmonary emboli (ie, group 4 PH phenotype). (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension", section on 'Computed pulmonary arteriography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventilation-perfusion (V/Q) scan</strong> – In most patients, we also obtain a V/Q scan, if not already performed. This is the preferred imaging modality to exclude chronic thromboembolic PH (CTEPH; ie, group 4 PH due to CTEPH), but it can also help identify significant regional flow disturbance from mediastinal lymphadenopathy in SAPH [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/8254.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension", section on 'Ventilation perfusion lung scanning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET)</strong> – We also evaluate most patients with SAPH using fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET). FDG-PET together with CT chest and V/Q scanning may further inform the clinician about any contribution from cardiac inflammation or extrinsic compression of the pulmonary vasculature (ie, contribution of group 4 PH phenotype). For example, if compressive lymphadenopathy is FDG-PET-active, PH may be responsive to anti-inflammatory therapy. (See  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults", section on 'PH with vascular obstruction or thromboembolism'</a>.)</p><p></p><p class="bulletIndent1">In the evaluation of SAPH, it has been proposed that FDG-PET identifies persistent (potentially reversible) granulomatous inflammation in areas otherwise believed to represent scarred areas in chest radiograph stage 4 pulmonary sarcoidosis [<a href="#rid73">73,74</a>]. Absence of FDG uptake suggests nonviable fibrosis and can be used as justification to not expose a patient to anti-inflammatory therapy. (See  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults", section on 'Anti-inflammatory therapy'</a> and  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Less commonly needed imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac magnetic resonance imaging (MRI)</strong> – If cardiac sarcoidosis needs to be excluded (eg, group 2 PH phenotype), we perform cardiac MRI. Cardiac MRI is the technique of choice in the evaluation of patients with suspected cardiac sarcoid. Cardiac MRI can help discern the contribution of cardiac disease to SAPH (eg, those with symptoms or signs suggestive of group 2 PH). Some clinicians also additionally perform FDG-PET for this reason. (See  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polysomnography</strong> – We perform polysomnography in patients with increased probability of having obstructive sleep apnea (OSA; obesity, poor nonrestorative sleep, positive screening questionnaires). For those in whom OSA testing is not indicated, we perform continuous overnight oximetry to look for nocturnal desaturation that may occur in association with underlying pulmonary disease. Indications for sleep testing are provided separately. (See  <a class="medical medical_review" href="/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other tests</strong> – Other postdiagnostic tests that may need to be considered during the classification phase of evaluation are discussed separately (eg, human immune deficiency testing, liver function tests). (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'</a>.)</p><p></p><p class="headingAnchor" id="H1453211482"><span class="h1">EARLY DETECTION OF SAPH</span><span class="headingEndMark"> — </span>We do <strong>not</strong> routinely perform transthoracic echocardiography (TTE) on asymptomatic patients with sarcoidosis or patients in whom there is no suspicion for PH. Rather, we have a low threshold to perform TTE in patients who are considered at risk for developing PH as a complication of their disease. These risk factors are discussed above  (<a class="graphic graphic_table graphicRef142511" href="/d/graphic/142511.html" rel="external">table 4</a>). (See <a class="local">'Identification of at-risk patients'</a> above.)</p><p class="headingAnchor" id="H2488354909"><span class="h1">SOCIETY GUIDELINE LINKS</span></p><p>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116637.html" rel="external">"Society guideline links: Sarcoidosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a>.)</p><p class="headingAnchor" id="H3250675653"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – Sarcoidosis-associated pulmonary hypertension (SAPH) is a clinically important complication of sarcoidosis that is associated with increased morbidity and mortality. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SAPH affects approximately 5 percent of patients with sarcoidosis and tends to be a late complication. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several mechanisms contribute to the development of SAPH, including cardiac sarcoidosis, diffuse lung parenchymal disease, and involvement of the pulmonary vasculature (eg, vasculopathy, thromboembolism, vascular obstruction/compression, granulomatous angiitis). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>At-risk patients</strong> – Once sarcoidosis is diagnosed, we evaluate patients for the risk of developing pulmonary hypertension (PH).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – We use clinical evaluation, pulmonary function tests, imaging features, oxygenation indices, and parameters of right ventricular strain/failure (eg, brain natriuretic peptide, electrocardiography) to identify those with sarcoidosis who are at risk of developing SAPH. (See <a class="local">'Identification of at-risk patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk factors</strong> – Factors derived from that evaluation that are associated with an increased risk of SAPH are listed in the table  (<a class="graphic graphic_table graphicRef142511" href="/d/graphic/142511.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing</strong> – Once SAPH is suspected, it is prudent that the patient be evaluated by sarcoidosis and PH experts who can jointly devise an appropriate diagnostic strategy for each individual patient.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transthoracic echocardiography (TTE)</strong> – For patients in whom clinical features and initial testing support SAPH, we perform TTE  (<a class="graphic graphic_table graphicRef142511" href="/d/graphic/142511.html" rel="external">table 4</a>). We do <strong>not</strong> perform TTE in asymptomatic patients or patients without supportive features of SAPH. (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Transthoracic echocardiography (TTE)'</a> above and <a class="local">'Early detection of SAPH'</a> above.)</p><p></p><p class="bulletIndent2">TTE determines the probability of PH (low, intermediate, or high probability) and is interpreted in a similar fashion to that in patients with suspected non-sarcoidosis-related PH  (<a class="graphic graphic_table graphicRef120360" href="/d/graphic/120360.html" rel="external">table 5</a>). This evaluation is discussed separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Echocardiography'</a>.)</p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Low probability of pulmonary hypertension on echocardiography'</a>.)</p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Intermediate or high probability of pulmonary hypertension on echocardiography (assess left heart)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Right heart catheterization (RHC)</strong> – The decision to proceed with RHC is similar in principle to that in patients without sarcoidosis in whom PH is suspected. These details are provided separately. (See  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Right heart catheterization'</a>.)</p><p></p><p class="bulletIndent2">However, in general, our threshold to perform RHC is lower in this population since it can distinguish precapillary (group 1, 3, and 4 PH phenotypes) from postcapillary disease (group 2 PH phenotype)  (<a class="graphic graphic_table graphicRef105764" href="/d/graphic/105764.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) and determine whether PH is multifactorial in nature. TTE, clinical suspicion for SAPH, and the impact of testing on the decision to implement potential future therapies determine the need for RHC. (See <a class="local">'Selecting patients for right heart catheterization'</a> above.)</p><p></p><p class="bulletIndent2">In brief our approach is the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with a low probability of having PH on TTE, we do not generally perform RHC.</p><p class="bulletIndent3"><span class="glyph">-</span>In patients with a high probability of PH on TTE, we perform RHC unless the results would not change management.</p><p class="bulletIndent3"><span class="glyph">-</span>In patients with an intermediate probability of PH or inconclusive TTE, we assess the need for RHC on a case-by-case basis.</p><p class="bulletIndent3"><span class="glyph">-</span>In addition, select features on clinical evaluation may also prompt RHC (eg, evaluation for lung transplantation, unexplained dyspnea, assessment of the potential contribution of cardiac and pulmonary parenchymal sarcoidosis to PH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> <strong>and postdiagnostic phenotyping</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – A definitive diagnosis of SAPH is made on RHC findings that demonstrate an elevated mean pulmonary artery pressure &gt;20 mmHg supine and at rest. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Definition and classification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phenotyping</strong> – Identifying a dominant etiology/phenotype is important for assigning a therapeutic plan. SAPH is generally classified as group 5 PH  (<a class="graphic graphic_table graphicRef66348" href="/d/graphic/66348.html" rel="external">table 1</a>) since the pathogenesis is often multifactorial. However, patients with sarcoidosis may also have a predominant PH class phenotype. For this assessment, we use existing data and obtain additional adjunctive testing, if needed. Additional detail is provided separately. (See <a class="local">'Postdiagnostic testing and phenotyping'</a> above and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e26.</a></li><li><a class="nounderline abstract_t">Savale L, Huitema M, Shlobin O, et al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev 2022; 31.</a></li><li><a class="nounderline abstract_t">Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Kaptan Özen D, Mutlu B, Kocakaya D, et al. Pulmonary hypertension in patients with sarcoidosis: A single-center experience. Anatol J Cardiol 2021; 25:36.</a></li><li><a class="nounderline abstract_t">Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128:1483.</a></li><li><a class="nounderline abstract_t">Keir GJ, Walsh SL, Gatzoulis MA, et al. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:82.</a></li><li><a class="nounderline abstract_t">Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32:296.</a></li><li><a class="nounderline abstract_t">Alhamad EH, Idrees MM, Alanezi MO, et al. Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients. Ann Thorac Med 2010; 5:86.</a></li><li><a class="nounderline abstract_t">Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129:1246.</a></li><li><a class="nounderline abstract_t">Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest 2018; 153:105.</a></li><li><a class="nounderline abstract_t">Pabst S, Grohé C, Skowasch D. Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25:783.</a></li><li><a class="nounderline abstract_t">Pabst S, Hammerstingl C, Grau N, et al. Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience. Adv Exp Med Biol 2013; 755:299.</a></li><li><a class="nounderline abstract_t">Huitema MP, Bakker ALM, Mager JJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J 2019; 54.</a></li><li><a class="nounderline abstract_t">Tiosano S, Versini M, Dar Antaki L, et al. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study. Clin Immunol 2019; 199:57.</a></li><li><a class="nounderline abstract_t">Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27:329.</a></li><li><a class="nounderline abstract_t">Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Baughman RP, Shlobin OA, Wells AU, et al. Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. Respir Med 2018; 139:72.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42.</a></li><li><a class="nounderline abstract_t">Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:108.</a></li><li><a class="nounderline abstract_t">Milman N, Svendsen CB, Iversen M, et al. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J 2009; 3:207.</a></li><li><a class="nounderline abstract_t">Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39:1520.</a></li><li><a class="nounderline abstract_t">Mathijssen H, Huitema MP, Bakker ALM, et al. Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension. Heart Lung Circ 2021; 30:1502.</a></li><li><a class="nounderline abstract_t">Ozyilmaz E, Akilli R, Berk İ, et al. The frequency of diastolic dysfunction in patients with sarcoidosis and it's relationship with HLA DRB1* alleles. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36:285.</a></li><li><a class="nounderline abstract_t">Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109:62.</a></li><li><a class="nounderline abstract_t">Angomachalelis N, Hourzamanis A, Vamvalis C, Gavrielides A. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J 1992; 68 Suppl 1:S52.</a></li><li><a class="nounderline abstract_t">Cozier YC, Govender P, Berman JS. Obesity and sarcoidosis: consequence or contributor? Curr Opin Pulm Med 2018; 24:487.</a></li><li><a class="nounderline abstract_t">Martusewicz-Boros MM, Boros PW, Wiatr E, Roszkowski-Śliż K. What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32:115.</a></li><li><a class="nounderline abstract_t">Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.</a></li><li><a class="nounderline abstract_t">Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120:873.</a></li><li><a class="nounderline abstract_t">Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68.</a></li><li><a class="nounderline abstract_t">Smith LJ, Lawrence JB, Katzenstein AA. Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci 1983; 285:38.</a></li><li><a class="nounderline abstract_t">Carrington CB. Structure and function in sarcoidosis. Ann N Y Acad Sci 1976; 278:265.</a></li><li><a class="nounderline abstract_t">Rosen Y, Moon S, Huang CT, et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101:170.</a></li><li><a class="nounderline abstract_t">Takemura T, Matsui Y, Oritsu M, et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A Pathol Anat Histopathol 1991; 418:361.</a></li><li><a class="nounderline abstract_t">Padia SA, Budev M, Farver CF, Mohammed TL. Intravascular sarcoidosis presenting as pulmonary vein occlusion: CT and pathologic findings. J Thorac Imaging 2007; 22:268.</a></li><li><a class="nounderline abstract_t">Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134:809.</a></li><li><a class="nounderline abstract_t">Schachter EN, Smith GJ, Cohen GS, et al. Pulmonary granulomas in a patient with pulmonary veno-occlusive disease. Chest 1975; 67:487.</a></li><li><a class="nounderline abstract_t">Jones RM, Dawson A, Jenkins GH, et al. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009; 34:517.</a></li><li><a class="nounderline abstract_t">Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78:888.</a></li><li><a class="nounderline abstract_t">Hasegawa K, Ohno S, Takada M, et al. Sarcoidosis complicated with major pulmonary artery obstruction and stenosis. Intern Med 2012; 51:2775.</a></li><li><a class="nounderline abstract_t">Toonkel RL, Borczuk AC, Pearson GD, et al. Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature. Respiration 2010; 79:341.</a></li><li><a class="nounderline abstract_t">Bazmpani MA, Arsos G, Zarogoulidis P, et al. A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension. Pulm Circ 2018; 8:2045894018768289.</a></li><li><a class="nounderline abstract_t">Morawiec E, Hachulla-Lemaire AL, Chabrol J, et al. Venoatrial compression by lymphadenopathy in sarcoidosis. Eur Respir J 2010; 35:1188.</a></li><li><a class="nounderline abstract_t">Gomes M, Bendaoud S, Wemeau-Stervinou L, et al. Prevalence of Venoatrial Compression by Lymphadenopathy in Sarcoidosis. J Thorac Imaging 2015; 30:268.</a></li><li><a class="nounderline abstract_t">Crawshaw AP, Wotton CJ, Yeates DG, et al. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66:447.</a></li><li><a class="nounderline abstract_t">Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140:1261.</a></li><li><a class="nounderline abstract_t">Ungprasert P, Crowson CS, Matteson EL. Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013. Chest 2017; 151:425.</a></li><li><a class="nounderline abstract_t">Tandon R, Baughman RP, Stanley J, Khan AA. The link between chronic thromboembolic pulmonary hypertension and sarcoidosis: association or visual masquerade? Sarcoidosis Vasc Diffuse Lung Dis 2017; 34:352.</a></li><li><a class="nounderline abstract_t">Verbraecken J, Hoitsma E, van der Grinten CP, et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:137.</a></li><li><a class="nounderline abstract_t">Pihtili A, Bingol Z, Kiyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath 2013; 17:1281.</a></li><li><a class="nounderline abstract_t">Bingol Z, Pihtili A, Gulbaran Z, Kiyan E. Relationship between parenchymal involvement and obstructive sleep apnea in subjects with sarcoidosis. Clin Respir J 2015; 9:14.</a></li><li><a class="nounderline abstract_t">Mavroudi M, Papakosta D, Kontakiotis T, et al. Sleep disorders and health-related quality of life in patients with interstitial lung disease. Sleep Breath 2018; 22:393.</a></li><li><a class="nounderline abstract_t">Mari PV, Pasciuto G, Siciliano M, et al. Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37:169.</a></li><li><a class="nounderline abstract_t">Cornet A, Barbier JP, Debesse B, et al. [Sarcoidosis and portal and pulmonary arterial hypertension: a case report (author's transl)]. Ann Med Interne (Paris) 1980; 131:431.</a></li><li><a class="nounderline abstract_t">Salazar A, Mañá J, Sala J, et al. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994; 61:117.</a></li><li><a class="nounderline abstract_t">Rapti A, Kouranos V, Gialafos E, et al. Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung 2013; 191:61.</a></li><li><a class="nounderline abstract_t">Mirsaeidi M, Omar HR, Baughman R, et al. The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33:317.</a></li><li><a class="nounderline abstract_t">Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in sarcoidosis. Postgrad Med J 1982; 58:282.</a></li><li><a class="nounderline abstract_t">Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111:278.</a></li><li><a class="nounderline abstract_t">Parikh KS, Dahhan T, Nicholl L, et al. Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. Sci Rep 2019; 9:4061.</a></li><li><a class="nounderline abstract_t">Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40:255.</a></li><li><a class="nounderline abstract_t">Jose A, Delio J, Gwizdala J, et al. Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2018; 35:308.</a></li><li><a class="nounderline abstract_t">Maimon N, Salz L, Shershevsky Y, et al. Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function. Int J Tuberc Lung Dis 2013; 17:406.</a></li><li><a class="nounderline abstract_t">Huitema MP, Spee M, Vorselaars VM, et al. Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. Eur Respir J 2016; 47:673.</a></li><li><a class="nounderline abstract_t">Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123.</a></li><li><a class="nounderline abstract_t">Shlobin OA, Kouranos V, Barnett SD, et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124:922.</a></li><li><a class="nounderline abstract_t">Handa T, Nagai S, Ueda S, et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:27.</a></li><li><a class="nounderline abstract_t">Huitema MP, Bakker ALM, Mager JJ, et al. Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography. Int J Cardiovasc Imaging 2020; 36:1497.</a></li><li><a class="nounderline abstract_t">Akaike G, Itani M, Shah H, et al. PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations. Radiographics 2018; 38:1536.</a></li><li><a class="nounderline abstract_t">Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:123.</a></li></ol></div><div id="topicVersionRevision">Topic 132051 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293205" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35140103" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545980" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary hypertension in chronic lung disease and hypoxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33382054" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pulmonary hypertension in patients with sarcoidosis: A single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162747" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078636" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385166" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical predictors of pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20582173" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685015" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728933" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictors of Mortality in Pulmonary Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32051184" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863633" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826080" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31320453" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30543925" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342757" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29051269" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29858005" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355641" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Definitions and diagnosis of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17937106" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20298406" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241743" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33933365" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476964" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The frequency of diastolic dysfunction in patients with sarcoidosis and it's relationship with HLA DRB1* alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549220" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1409217" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29979212" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Obesity and sarcoidosis: consequence or contributor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26278690" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348196" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555523" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227329" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6824015" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vascular sarcoidosis: a rare cause of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1067012" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Structure and function in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/576782" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Granulomatous pulmonary angiitis in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1850897" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721340" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intravascular sarcoidosis presenting as pulmonary vein occlusion: CT and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767134" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sarcoidosis simulating pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1122783" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pulmonary granulomas in a patient with pulmonary veno-occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648528" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7449474" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23037473" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sarcoidosis complicated with major pulmonary artery obstruction and stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797887" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sarcoidosis-associated fibrosing mediastinitis with resultant pulmonary hypertension: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29537341" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20436179" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Venoatrial compression by lymphadenopathy in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730555" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence of Venoatrial Compression by Lymphadenopathy in Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837871" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565969" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27687848" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476868" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The link between chronic thromboembolic pulmonary hypertension and sarcoidosis: association or visual masquerade?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15281435" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sleep disturbances associated with periodic leg movements in chronic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23563999" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Obstructive sleep apnea is common in patients with interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24405843" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relationship between parenchymal involvement and obstructive sleep apnea in subjects with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29038949" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sleep disorders and health-related quality of life in patients with interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093780" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7224452" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [Sarcoidosis and portal and pulmonary arterial hypertension: a case report (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008988" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Combined portal and pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229755" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079843" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7111113" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reversible pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290599" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858405" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441750" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sarcoidosis-associated fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476918" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407231" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493790" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503267" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139456" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970018" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Predicting mortality in patients with sarcoidosis awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21086902" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350704" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30118393" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22117503" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : 18F-FDG PET as a predictor of pulmonary function in sarcoidosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
